Michel Attal

Summary

Country: France

Publications

  1. ncbi request reprint Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:397-403. 2006
  2. ncbi request reprint Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
  3. doi request reprint Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
    Michel Attal
    Department of Hematology, Hopital Purpan, Toulouse, France
    N Engl J Med 366:1782-91. 2012
  4. doi request reprint The role of high-dose therapy with autologous stem cell support in the era of novel agents
    Michel Attal
    Centre Hospitalier de Purpan, Toulouse, France
    Semin Hematol 46:127-32. 2009
  5. ncbi request reprint Single versus double autologous stem-cell transplantation for multiple myeloma
    Michel Attal
    Department of Hematology and Biostatistics, Hopital Purpan, Toulouse, France
    N Engl J Med 349:2495-502. 2003
  6. doi request reprint Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
    Murielle Roussel
    Hopital Purpan, Toulouse, France
    Blood 115:32-7. 2010
  7. doi request reprint Firstline treatment and maintenance in newly diagnosed multiple myeloma patients
    Murielle Roussel
    Hématologie Clinique, CHU Purpan, Toulouse, France
    Recent Results Cancer Res 183:189-206. 2011
  8. ncbi request reprint Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
  9. ncbi request reprint Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra
    Philippe Moreau
    Service d Hematologie, University Hospital Hotel Dieu, Place Alexis Recordeau, 44093 Nantes Cedex 01, France
    Blood 99:731-5. 2002
  10. doi request reprint Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission
    Norbert Claude Gorin
    Department of Hematology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris, France
    Blood 116:3157-62. 2010

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:397-403. 2006
    ..39). In high-risk patients the dose intensity of melphalan at 420 mg/m2 led to encouraging results, but the addition of anti-IL-6 monoclonal antibody to the second conditioning regimen did not improve either OS nor EFS...
  2. ncbi request reprint Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
    ..4). Thalidomide is an effective maintenance therapy in patients with multiple myeloma. Maintenance treatment with pamidronate does not decrease the incidence of bone events...
  3. doi request reprint Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
    Michel Attal
    Department of Hematology, Hopital Purpan, Toulouse, France
    N Engl J Med 366:1782-91. 2012
    ..Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation...
  4. doi request reprint The role of high-dose therapy with autologous stem cell support in the era of novel agents
    Michel Attal
    Centre Hospitalier de Purpan, Toulouse, France
    Semin Hematol 46:127-32. 2009
    ..Finally, the issue of HDT in the era of new drug regimens is discussed, as well as the necessity of designing future trials comparing HDT and new drug regimens...
  5. ncbi request reprint Single versus double autologous stem-cell transplantation for multiple myeloma
    Michel Attal
    Department of Hematology and Biostatistics, Hopital Purpan, Toulouse, France
    N Engl J Med 349:2495-502. 2003
    ..We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations...
  6. doi request reprint Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
    Murielle Roussel
    Hopital Purpan, Toulouse, France
    Blood 115:32-7. 2010
    ..Randomized studies are needed to assess whether this conditioning regimen is superior to HDM alone. This trial was registered at www.clinicaltrials.gov as NCT00642395...
  7. doi request reprint Firstline treatment and maintenance in newly diagnosed multiple myeloma patients
    Murielle Roussel
    Hématologie Clinique, CHU Purpan, Toulouse, France
    Recent Results Cancer Res 183:189-206. 2011
    ..Melphalan-prednisone-thalidomide and bortezomib-melphalan-prednisone are the two standards of care. Current trials are challenging the role of alkylators in the frontline setting. Maintenance therapy is also undergoing evaluation...
  8. ncbi request reprint Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
    ..We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival...
  9. ncbi request reprint Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra
    Philippe Moreau
    Service d Hematologie, University Hospital Hotel Dieu, Place Alexis Recordeau, 44093 Nantes Cedex 01, France
    Blood 99:731-5. 2002
    ..This regimen should be considered as the standard of care before autologous stem cell transplantation in multiple myeloma...
  10. doi request reprint Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission
    Norbert Claude Gorin
    Department of Hematology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris, France
    Blood 116:3157-62. 2010
    ..72; 95% confidence interval, 0.55-0.93; P = .01). In conclusion, in patients autografted in first remission, relapse was higher and leukemia-free survival lower for those who received the highest CD34(+) PB doses...
  11. doi request reprint Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma
    Jill Corre
    Institut National de la Sante et de la Recherche Medicale, U1037, Toulouse, France
    Cancer Res 72:1395-406. 2012
    ....
  12. doi request reprint Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission
    Norbert Claude Gorin
    Hopital Saint Antoine, Department of Hematology, Paris, France
    J Clin Oncol 27:3987-93. 2009
    ..In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source...
  13. doi request reprint Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood an
    Norbert Claude Gorin
    Department of Hematology, Hopital Saint Antoine and Université Pierre et Marie Curie UPMC, 184 rue du Faubourg Saint Antoine, Cedex 12 Paris, France
    J Clin Oncol 26:3183-8. 2008
    ..They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses...
  14. ncbi request reprint Role of autologous stem-cell transplantation in multiple myeloma
    Michel Attal
    Hematology Department, Centre Hospitalier de Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Best Pract Res Clin Haematol 20:747-59. 2007
    ..This article will focus on the current results of ASCT and will discuss the main research area to try to improve this strategy...
  15. ncbi request reprint Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    Herve Tilly
    Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
    Blood 102:4284-9. 2003
    ..004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival...
  16. doi request reprint Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
    Mauricette Michallet
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Exp Hematol 36:535-44. 2008
    ..In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility...
  17. ncbi request reprint Stem-cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    Best Pract Res Clin Haematol 18:603-18. 2005
    ..The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied...
  18. ncbi request reprint High-dose therapy in multiple myeloma
    Jean Luc Harousseau
    Centre Hospitalier Universitaire, Service d Hematologie, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Hematol J 4:163-70. 2003
  19. doi request reprint Dual-energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma
    Michel Laroche
    Service de Rhumatologie, Centre Hospitalier Universitaire Purpan, Toulouse, France
    Eur J Haematol 88:388-95. 2012
    ..To evaluate the effect of high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) on bone turnover and bone mineral density in a cohort of 39 consecutive patients with multiple myeloma (MM)...
  20. ncbi request reprint The role of stem cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Centre Hospitalier Universitaire, Service d Hematologie, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Blood Rev 16:245-53. 2002
    ..Therefore, the objectives of current studies is to reduce transplant related mortality by using earlier BMT, better selection of patients, better graft-versus host prophylaxis or non myeloablative conditioning regimens...
  21. doi request reprint Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies
    Philippe Moreau
    Centre Hospitalier Universitaire Nantes, Nantes, France
    J Clin Oncol 29:1898-906. 2011
    ....
  22. pmc Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Toulouse, France
    J Clin Oncol 31:2806-9. 2013
    ..However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy...
  23. doi request reprint Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma
    Michel Laroche
    Rheumatology Department, Purpan University Hospital, Toulouse, France
    Eur J Haematol 85:65-7. 2010
    ..In this study, we aimed to determine the prevalence of vitamin D deficiency and to assess its impact on bone remodelling and bone mineral density before and after autologous stem cell transplantation (ASCT)...
  24. ncbi request reprint Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
    Frederic Garban
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:3474-80. 2006
    ..2 vs 35 months; P = .07). In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose-intensified, melphalan-based ASCT...
  25. doi request reprint Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
    Sarah Bertoli
    Service d Hematologie, Centre Hospitalier Universitaire de Toulouse, Hopital Purpan, Toulouse, France
    Blood 121:2618-26. 2013
    ..Furthermore, TDT was not associated with response rate and early death. Thus, waiting a short period of time for laboratory tests to characterize leukemias better and design adapted therapeutic strategies at diagnosis seems possible...
  26. doi request reprint Hepatitis E virus excretion can be prolonged in patients with hematological malignancies
    Suzanne Tavitian
    Service d Hematologie, CHU de Toulouse, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse Cedex, France
    J Clin Virol 49:141-4. 2010
    ..Chronic hepatitis E virus infections have been recently described in solid organ transplant recipients. There is little data on the evolution of hepatitis E in patients immunocompromised for other reasons...
  27. doi request reprint Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire
    Steven Le Gouill
    Hematology Department, University Hospital, Hotel Dieu, Nantes, France
    J Clin Oncol 26:2264-71. 2008
    ..Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas...